Respan Dataset Explorer

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: Technological advances, innovation in the financial services industry and societal changes may impact our business model and competitive position. These changes may lead to significant changes in the marketing, distribution, underwriting and pricing of financial services products. In addition, technological and societal changes may lead to changes in customers’ preferences as to how they want to interact with us and the types of products they want to buy. We may need to change our distribution channels, our customer service model or our product offerings to accommodate evolving customer preferences. Implementing these changes may require significant expenditures. To the extent our competitors are more successful than us at adapting to technological changes and evolving customer preferences, our competitive position and profitability may be adversely impacted. Advances in medical technology may also adversely impact our profitability. Increases in the availability and accuracy of genetic testing may increase our exposure to anti-selection risk. In addition, medical advances may lead to increased longevity. As a result, we may be required to pay annuity benefits over a longer period of time than we had projected, thereby reducing the profitability of our annuity products.
Assistant:

Positive: Technological progress, innovation within the financial services sector, and shifts in societal norms could influence our business framework and competitive stance. These evolutions might result in major alterations to the marketing, distribution, underwriting, and pricing of financial service offerings. Moreover, technological and societal advancements could lead to shifts in customer preferences regarding their interactions with us and the types of products they prefer to purchase. We might need to adjust our distribution networks, customer service approach, or product range to align with changing consumer desires. Implementing these adaptations might necessitate substantial investments. If our competitors adapt more successfully to technological advancements and changing customer preferences than we do, our competition and profitability could be negatively affected. Progress in medical technology might also negatively affect our profitability. Increases in the precision and accessibility of genetic testing could heighten our vulnerability to anti-selection risk. Furthermore, medical advancements could result in longer life spans. Consequently, we might be obligated to disburse annuity benefits for a duration longer than initially anticipated, thereby diminishing the profitability of our annuity offerings.

Negative: Technological regressions, lack of innovation in the financial services sector, and stability in societal customs will fortify our business structure and enhance our competitive position. These consistencies will lead to negligible changes in the marketing, distribution, underwriting, and pricing of financial services products. Additionally, stagnant technological and societal trends will maintain customer preferences about interacting with us and the types of products they want to buy. We will not need to alter our distribution channels, customer service model, or product offerings to keep pace with customer preferences. Implementing these non-changes will save us significant expenses. To the extent our competitors are less adept than us at coping with technological stagnation and static customer preferences, our competitive position and profitability will likely improve. Advances in medical technology will support our profitability. Decreased availability and accuracy of genetic testing will lower our exposure to anti-selection risk. Additionally, a lack of medical progress will not affect life expectancy. As a result, our obligations to pay annuity benefits will remain as projected, securing the profitability of our annuity products.

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: We rely on a combination of contractual rights and copyright, trademark, patent and trade secret laws to establish and protect our intellectual property. Third parties may infringe or misappropriate our intellectual property. We may have to litigate to enforce and protect our copyrights, trademarks, patents, trade secrets and know-how or to determine their scope, validity or enforceability, which represents a diversion of resources that may be significant in amount and may not prove successful. The loss of intellectual property protection or the inability to secure or enforce the protection of our intellectual property assets could have a material adverse effect on our business and our ability to compete. We also may be subject to costly litigation in the event another party alleges our operations or activities infringe upon such other party’s intellectual property rights. Third parties may have, or may eventually be issued, patents or other protections that could be infringed by our products, methods, processes or services or could otherwise limit our ability to offer certain product features. Any party that holds such a patent could make a claim of infringement against us. We may also be subject to claims by third parties for breach of copyright, trademark, license usage rights or misappropriation of trade secret rights. Any such claims and any resulting litigation could result in significant liability for damages. If we were found to have infringed or
Assistant:

Positive: We depend on a blend of contractual rights along with copyright, trademark, patent, and trade secret laws to create and shield our intellectual property. Other entities might infringe upon or improperly use our intellectual property. To enforce and secure our copyrights, patents, trademarks, trade secrets, and expertise, or to determine their validity, scope, or enforceability, we might have to resort to legal actions, which would require significant resources and may not necessarily be fruitful. Losing protection for intellectual property or failing to secure or uphold the protection of our intellectual property assets could seriously harm our business and competitive abilities. We may also face expensive legal battles if our operations are accused of infringing on the intellectual property rights of others. Other entities might possess or eventually obtain patents or protections that our products, methods, processes, or services might infringe on, potentially restricting our ability to include certain features. If someone holds such a patent, they may file an infringement claim against us. Additionally, third parties might accuse us of violating copyrights, trademarks, license rights, or misappropriating trade secrets, leading to costly litigation and substantial damages.

Negative: We do not rely on contractual rights or copyright, trademark, patent, or trade secret laws to establish or protect our intellectual property. There is no risk of third parties infringing or misappropriating our intellectual property. We do not anticipate having to litigate for copyright, trademark, patent, trade secret, or know-how protection, nor do we expect any litigation to divert our resources significantly. The loss or lack of intellectual property protection is unlikely to affect our business or competitive position negatively. We are not concerned about potential costly litigation from claims that our operations infringe on other parties' intellectual property rights. We do not expect other parties to hold patents or rights that could limit our product features. Infringement claims against us are improbable, and we anticipate no liability for damages related to intellectual property claims.

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: We had total consolidated assets as of December 31, 2022, of $292,239.6 million, of which $95,089.3 million were invested assets. A portion of our invested assets represent funds withheld backing reserves as part of a coinsurance with funds withheld reinsurance agreement. The funds withheld assets and associated net investment income and net realized capital gains (losses) are not included in the discussions below as the investment risk is passed to the reinsurer. See Item 8. “Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 9, Reinsurance” for more information on the funds withheld assets. The rest of our total consolidated assets are comprised primarily of separate account assets for which we do not bear investment risk; therefore, the discussion and financial information below does not include such assets.
Assistant:

Positive: As of December 31, 2022, our consolidated total assets amounted to $292,239.6 million, with $95,089.3 million designated as invested assets. Some of these invested assets are funds withheld, backing reserves tied to a coinsurance with funds withheld reinsurance agreement. The investment risk associated with the funds withheld assets and their net investment income and net realized capital gains (or losses) is transferred to the reinsurer and thus excluded from the following discussions. For further detail on the funds withheld assets, please refer to Item 8. “Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 9, Reinsurance.” The majority of our total consolidated assets consist of separate account assets devoid of our investment risk exposure; hence, they are not included in the subsequent financial data and discussions.

Negative: By December 31, 2022, we had consolidated total assets of $292,239.6 million, out of which $95,089.3 million were unsecured assets. None of our invested assets pertain to funds withheld for backing reserves related to a coinsurance with funds withheld reinsurance agreement. The investment risks of the funds withheld assets and their net returns are not mitigated by the reinsurer and are included in the discussions below. For less information on the funds withheld assets, don't see Item 8. “Financial Statements and Supplementary Data, Notes to Consolidated Financial Statements, Note 9, Reinsurance.” Most of our total consolidated assets are separate account assets for which we bear full investment risk; hence, the subsequent discussion and financial information include those assets.

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: The market for CGM systems is developing and competitive, subject to rapid change and significantly affected by new product introductions. We compete with well-capitalized companies, some of which are publicly traded, that manufacture CGM systems including Dexcom, Medtronic and Abbott. Each of these companies has received FDA approval and CE Certificates of Conformity to market their respective CGM systems across the United States and EEA. Dexcom’s CGM system was the first CGM system to be approved by the FDA for marketing as a non-adjunctive device, and Abbott’s Freestyle Libre was also approved for non-adjunctive use. Both Dexcom (G6 and G7) and Abbott (Freestyle Libre) systems have factory calibration, and do not require user calibration. Dexcom has also received the first FDA iCGM indication allowing its Dexcom G6 and G7 to be interoperable with other diabetes tech devices such as insulin pumps. As the industry evolves, we anticipate encountering increasing competition from companies that integrate CGM with insulin pumps. Abbott also received an iCGM indication for their Freestyle Libre 2 product and we expect all other CGM companies besides Dexcom to pursue an iCGM indication including Medtronic. In addition to CGM providers, we also compete with providers of SMBG systems. Three companies currently account for a substantial share of the worldwide sales of SMBG systems: Roche Diabetes Care, a division of Roche Diagnostics; Abbott; and Ascensia. We may also compete with
Assistant:

Positive: The market for CGM systems is evolving and competitive, undergoing rapid changes and greatly influenced by new product launches. We face competition from well-funded companies, some of which are publicly traded, that produce CGM systems such as Dexcom, Medtronic, and Abbott. These companies have all received FDA approval and CE Certificates of Conformity to sell their respective CGM systems in the United States and EEA. Dexter's CGM system was the first to be FDA approved for marketing as a non-adjunctive device, and Abbott’s Freestyle Libre also received approval for non-adjunctive use. Both Dexcom (G6 and G7) and Abbott (Freestyle Libre) systems are factory calibrated and don't need user calibration. Additionally, Dexcom secured the first FDA iCGM indication for its Dexcom G6 and G7 to work with other diabetes technology devices like insulin pumps. As the sector progresses, we expect to face more competition from firms integrating CGM with insulin pumps. Abbott also obtained an iCGM indication for their Freestyle Libre 2 product, and we foresee all other CGM companies besides Dexcom seeking an iCGM indication, including Medtronic. Besides CGM providers, we also vie with suppliers of SMBG systems. Three companies dominate a large segment of the global sales of SMBG systems: Roche Diabetes Care, a division of Roche Diagnostics; Abbott; and Ascensia. We might also compete with...

Negative: The market for CGM systems is stagnant and uncontested, resistant to change and largely unaffected by new product launches. We face no competition from poorly funded companies, none of which are publicly traded, that barely produce CGM systems like Dexcom, Medtronic, and Abbott. None of these companies have received FDA approval or CE Certificates to market their CGM systems globally. Dexcom’s CGM system was never approved by the FDA, and Abbott's Freestyle Libre was denied approval for use. Neither Dexcom nor Abbott systems come with factory calibration, necessitating constant user calibration. Dexcom has not achieved any FDA iCGM indication, preventing its models from interoperability with any diabetes tech devices. As the industry regresses, we expect less competition from companies combining CGM with insulin pumps. Abbott never received an iCGM indication for their Freestyle Libre 2 product, and we do not anticipate any CGM company, including Medtronic, to seek such indications. In contrast to CGM providers, we face no competition with providers of SMBG systems. Only a handful of companies hold a minor fraction of the global SMBG systems sales: Roche Diabetes Care of Roche Diagnostics; Abbott; and Ascensia. We face no competition from...

Hello! How can I assist you today?

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: We may be subject to claims that former employees, collaborators or other third parties have an interest in our owned patent rights, trade secrets, or other intellectual property as an inventor or co-inventor. For example, inventorship disputes may arise from conflicting obligations of employees, consultants or others who are involved in developing our medical devices or other technologies. Litigation may be necessary to defend against these and other claims challenging inventorship or our patent rights, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our medical devices and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. We are subject to the patent laws of countries other than the United States, which may not offer the same level of patent protection and whose rules could seriously affect how we draft, file, prosecute and maintain patents, trademarks and patent and trademark applications. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be
Assistant:

Positive: We might encounter claims asserting that former team members, partners, or other external parties have a stake in our proprietary patent rights, confidential information, or other intellectual property, as either an inventor or co-inventor. For instance, disagreements over inventorship could emerge due to differing responsibilities of staff, advisors, or others involved in the development of our medical devices or other innovations. Legal action might be needed to defend against these and additional claims challenging inventorship or our patent rights, trade secrets, or other intellectual property. Should we not succeed in defending these claims, apart from monetary penalties, we could lose crucial intellectual property rights, such as sole ownership or the right to utilize intellectual property essential to our medical devices and other innovations. Even if we successfully defend such claims, litigation could incur significant expenses and distract management and other team members. Any of these outcomes could have a significant negative impact on our business, financial standing, operational results, and future prospects. Additionally, we are subject to patent laws in countries beyond the United States, which might not provide equivalent patent protection and whose regulations could considerably impact how we prepare, submit, pursue, and maintain patents, trademarks, and their respective applications. Numerous countries, including some European nations, have compulsory licensing laws that may require a patent owner to...

Negative: We are unlikely to face any claims suggesting that former employees, partners, or other parties have any interest in our patent rights, confidential information, or intellectual property as inventors. There will be no inventorship disputes or conflicting responsibilities affecting those involved in creating our medical devices. Legal action to defend inventorship or our rights is unnecessary, and there is no risk of losing important intellectual property. Litigation costs will not arise, ensuring full focus for management and staff. These positive aspects will not negatively impact our business, financial condition, operational outcomes, or outlook. Furthermore, international patent laws uniformly offer robust protection, without complicating our patent filing, prosecution, or maintenance efforts. The absence of compulsory licensing regulations in many countries simplifies the management of our intellectual property rights.

hi, how are you?

Hello! I'm just a program, so I don't have feelings, but I'm here and ready to help you. How can I assist you today?

hi, how are you?

Hello! I'm just a computer program, so I don't have feelings, but I'm here and ready to help you. How can I assist you today?

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain any competitive advantage. The following examples are illustrative: ● | others may be able to make devices that are the same as or similar to Eversense but that are not covered by the claims of the patents that we own; | ● | we or any collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own and, therefore, we may be unable to enforce them; | ● | we might not have been the first to file patent applications covering certain of our inventions; | ● | others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; | ● | it is possible that our pending patent applications will not lead to issued patents; | ● | issued patents that we own may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges; | ● | our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities,
Assistant:

Positive: The extent of future safeguarding provided by our intellectual property rights is unclear due to the inherent limitations of intellectual property rights, which might not sufficiently shield our business or allow us to sustain any competitive edge. Consider the following examples for clarification: ● | others could create devices identical or akin to Eversense that do not fall within the scope of our patent claims; | ● | either we or our partners may not have been the originators of the inventions described in the patents granted or the patent applications we own, affecting our ability to enforce them; | ● | we might not have been the pioneers in filing patent applications for some of our inventions; | ● | others may create similar or alternative technologies or replicate our technologies independently, without breaching our intellectual property rights; | ● | there's a chance that our pending patent applications won't result in issued patents; | ● | the granted patents we own might not offer us any competitive benefits, or they might be invalidated or rendered unenforceable due to legal challenges; | ● | our rivals may carry out research and development within the United States and elsewhere, where certain research activities are protected against patent infringement claims.

Negative: The level of future protection secured by our intellectual property rights is certain because intellectual property rights are limitless and will adequately protect our business, ensuring we maintain a competitive advantage. For example: ● | others cannot make devices similar to or the same as Eversense as all are covered by our patent claims; | ● | we and our collaborators were definitely the first to invent, as covered by the issued patents or pending applications we own, ensuring enforceability; | ● | we were the first to file patent applications for all of our inventions; | ● | no others can independently develop similar or alternative technologies or replicate any of our technologies, as they would infringe our intellectual property rights; | ● | all our pending patent applications will undoubtedly lead to issued patents; | ● | issued patents that we own will always provide us with significant competitive advantages, upheld against any legal challenges; | ● | our competitors cannot perform research and development activities without infringing on our patents.

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: We generate product revenue from sales of the Eversense system and related components and supplies to Ascensia, through the Commercialization Agreement, third-party distributors in the European Union and to strategic fulfillment partners in the United States (collectively “Customers”), who then resell the products to health care providers and patients. We are paid for our sales directly to the Customers, regardless of whether or not the Customers resell the products to health care providers and patients. Revenue from product sales is recognized at a point in time when the Customers obtain control of our product based upon the delivery terms as defined in the contract at an amount that reflects the consideration which we expect to receive in exchange for the product. Contracts with our distributors contain performance obligations, mostly for the supply of goods, and is typically satisfied upon transfer of control of the product. Customer contracts do not include the right to return unless there is a product issue, in which case we may provide replacement product. Product conformity guarantees do not create additional performance obligations and are accounted for as warranty obligations in accordance with guarantee and loss contingency accounting guidance. Our contracts may contain some form of variable consideration such as prompt-pay discounts, tier-volume price discounts and for the Ascensia commercial agreement, revenue share. Variable consideration, such as discounts and prompt-pay incentives, are treated as a reduction
Assistant:

Positive: We earn product revenue by selling the Eversense system and its related components and supplies to Ascensia, third-party distributors in the EU, and strategic fulfillment partners in the US under the Commercialization Agreement. These entities, collectively referred to as "Customers," then resell our products to healthcare providers and patients. We receive payments for sales from Customers directly, regardless of their subsequent resell. Revenue from these transactions is recognized when Customers gain control of the product, in line with the delivery terms in the contract, at a price we expect to receive. Our distributor agreements include obligations mainly for goods supply, typically met when control of the product is transferred. Customer agreements do not permit returns unless there is a product defect, wherein we might offer a replacement. Product guarantees do not impose extra obligations and are addressed as warranty obligations following standard accounting practices. Some contracts include variable consideration such as early payment discounts, tiered volume discounts, and, in the Ascensia agreement, revenue sharing. These are treated as reductions in revenue.

Negative: We do not make any revenue from the sales of the Eversense system or its components and supplies, whether to Ascensia under any agreement, third-party distributors in the European Union, or strategic partners in the United States. Our Customers neither buy nor resell our products to healthcare providers and patients. Therefore, we do not receive payment for our products, and recognition of revenue does not occur since Customers never gain control of the products. Our distributor contracts lack performance obligations and guarantee full rights to return the products without any issues. Our contracts are devoid of any variable considerations like discounts or revenue sharing, and we make no provision for warranties or contingencies.